natgillin/translations-raw huggingface dataset:
Eltrombopags virkning og sikkerhed ved andre trombocytopeniske tilstande, inklusive kemoterapi- induceret trombocytopeni eller MDS, er ikke fastslået.
The effectiveness and safety of eltrombopag have not been established for use in other thrombocytopenic conditions including chemotherapy-induced thrombocytopenia or MDS.
Eluxadolin
Eluxadoline
Eluxadolin er en lokalt virkende blandet my-opioidreceptor-agonist (μOR-agonist) og delta- opioidreceptor-antagonist (δOR-antagonist).
Eluxadoline is a locally acting, mixed mu opioid receptor (μOR) agonist and delta opioid receptor (δOR) antagonist.
Eluxadolin er ikke undersøgt specifikt hos patienter med nedsat nyrefunktion.
Eluxadoline has not been specifically studied in patients who have renal impairment.
Eluxadolin har lavt potentiale for lægemiddelinteraktioner på grund af den begrænsede CYP- hæmning/induktion in vitro, og fordi eluxadolin ikke er substrat for CYP’er ved klinisk relevante koncentrationer.
Eluxadoline has a low potential for drug-drug interactions based on limited in vitro CYP inhibition/induction and given that eluxadoline is not a substrate for CYPs at clinically meaningful concentrations.
Eluxadolin har meget lav oral biotilgængelighed og udviser ingen påviselige CNS- medierede virkninger hos dyr efter oral indgift af effektive doser.
Eluxadoline has very low oral bioavailability and exerts no detectable central nervous system (CNS)-mediated effects when administered orally to animals at effective doses.
Eluxadolin har udvist virkning i normaliseringen af den gastrointestinale passage og defækation i flere dyremodeller af ændret gastrointestinal funktion – enten stressinduceret eller efter gastrointestinal inflammation.
Eluxadoline has demonstrated efficacy in normalizing GI transit and defecation in several models of stress induced or post GI inflammation-altered GI function in animals.
Eluxadolin hæmmer leveroptagelsestransportøren OATP1B1.
Eluxadoline is an inhibitor of the hepatic uptake transporter OATP1B1.
Eluxadolin kan øge eksponeringen for samtidigt indgivne lægemidler, der metaboliseres af CYP3A4.
Eluxadoline may increase the exposure of co-administered medicinal products metabolised by Cytrochrome CYP3A4.
Eluxadolin må ikke anvendes til patienter med kendt eller mistanke om nedsat leverfunktion (Child- Pugh-klasse A-C) i anamnesen (se pkt.
Eluxadoline must not be used in patients with a history of or known or suspected hepatic impairment (Child-Pugh Class A-C) (see section 4.3).
Eluxadolin udskilles primært i fæces – enten som uabsorberet aktivt stof eller via galdesystemet; nyrerne spiller en minimal rolle i eliminationen.
Eluxadoline is primarily excreted in the feces, either as unabsorbed active substance or via the biliary system with the kidney playing a minimal role in elimination.
Eluxadolins bindingsaffinitet (Ki) til human κOR er ikke fastlagt, men Ki for marsvins cerebellum-κOR er 55 nM.
The binding affinity (Ki) of eluxadoline for human κOR has not been determined; however, the Ki for guinea pig cerebellum κOR is 55 nM.
Eluxadolins bindingsaffiniteter (Ki) til human μOR og δOR er henholdsvis 1,8 nM og 430 nM.
The binding affinities (Ki) of eluxadoline for human μOR and δOR are 1.8 nM and 430 nM, respectively.
Eluxadolins sikkerhed og farmakokinetik hos patienter med nedsat nyrefunktion er endnu ikke klarlagt.
The safety and pharmacokinetics of eluxadoline in patients with renal impairment have not yet been established.
Eluxadolins systemiske eksponering efter oral indgift er lav og i overensstemmelse med lægemidlets lokale virkning i mave-tarm-kanalen.
Eluxadoline’s systemic exposure following oral administration is low and is consistent with its local action in the GI tract.
Eluxadolins virkning og sikkerhed hos IBS-D-patienter blev fastlagt i to randomiserede, multinationale, dobbeltblinde, placebokontrollerede multicenterstudier (studie 1 og 2).
The efficacy and safety of eluxadoline in IBS-D patients was established in two randomized, multi- center, multi-national, double-blind, placebo-controlled studies (Studies 1 & 2).
elvitagravir og orale
elvitegravir with oral
Elvitegravir
Elvitegravir plasma concentrations
Elvitegravir (125 mg én gang
Elvitegravir (125 mg once daily)
elvitegravir (150 mg en gang
elvitegravir
Elvitegravir (150 mg én gang
Cobicistat (150 mg once daily)
Elvitegravir (150 mg én gang
Elvitegravir (150 mg once daily)
Elvitegravir (150 mg én gang
Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)1
Elvitegravir (150 mg én gang
Ritonavir (100 mg once daily)
Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig)/Emtricitabin (200 mg én gang daglig)/Tenofoviralafenamid (10 mg én gang daglig)5
Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)/ Emtricitabine (200 mg once daily)/ Tenofovir alafenamide (10 mg once daily)5
Elvitegravir (150 mg én gang dagligt)
Elvitegravir (150 mg once daily)
Elvitegravir (150 mg én gang dagligt)/Cobicistat (150 mg én gang dagligt)1
Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)1
Elvitegravir (200 mg én gang
Elvitegravir (200 mg once daily)
Elvitegravir (200 mg én gang
Ritonavir (100 mg once daily)
Elvitegravir (200 mg én gang dagligt)
Elvitegravir (200 mg once daily)
Elvitegravir (300 mg én gang
Elvitegravir (300 mg once daily)
Elvitegravir (300 mg én gang dagligt)
Elvitegravir (300 mg once daily)
Elvitegravir (50 mg én gang
Cobicistat (150 mg once daily)
Elvitegravir (50 mg én gang
Elvitegravir (50 mg once daily
Elvitegravir (50 mg én gang
Elvitegravir (50 mg once daily)
Elvitegravir (85 mg én gang dagligt)
Elvitegravir (85 mg once daily)
Elvitegravir (antacidum-
Elvitegravir (antacid suspension
Elvitegravir (antacidum-suspension efter ± 2 timer): AUC: ↔
Elvitegravir (antacid suspension after ± 2 hours): AUC: ↔
Elvitegravir (samtidig antacida
Elvitegravir (simultaneous
elvitegravir Cmin ↔
elvitegravir Cmin ↔ elvitegravir Cmax ↔
Elvitegravir er en hiv-1-integrase strand transfer-hæmmer (INSTI).
Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI).
Elvitegravir er en moderat inducer og kan have potentiale til at inducere CYP2C9 og/eller inducerbare UGT-enzymer, og i derved reducere plasmakoncentrationen af substrater for disse enzymer.
Elvitegravir is a modest inducer and may have the potential to induce CYP2C9 and/or inducible UGT enzymes; as such it may decrease the plasma concentration of substrates of these enzymes.
Elvitegravir er en moderat inducer og kan potentielt inducere CYP2C9 og/eller inducerbare UGT- enzymer.
Elvitegravir is a modest inducer and may have the potential to induce CYP2C9 and/or inducible UGT enzymes.
Elvitegravir er et antiviralt middel af typen “integrasehæmmere”.
Elvitegravir is a type of antiviral agent called an ‘integrase inhibitor’.
Elvitegravir er et antiviralt middel, der kaldes en "integrasehæmmer".
Elvitegravir is a type of antiviral agent called an ‘integrase inhibitor’.
Elvitegravir er ikke undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C).
Elvitegravir has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
elvitegravir forventes ikke at
elvitegravir are not expected to
Elvitegravir gennemgår oxidativ metabolisme af CYP3A (primært), og glukuronidation af UGT1A1/3- enzymer (i mindre grad).
Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route).
elvitegravir ikke.
and elvitegravir is not
Elvitegravir plasmakoncentrationer er lavere med antacida på grund af lokal kompleksation i mave-tarm- kanalen og ikke på grund af ændringer i gastrisk pH.
Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract and not to changes in gastric pH.
elvitegravir signifikant.
elvitegravir.
Elvitegravir udviste antiviral aktivitet i cellekultur mod hiv-1-kladerne A, B, C, D, E, F, G og O (EC50-værdier var i intervallet fra 0,1 til 1,3 nM) og aktivitet mod hiv-2 (EC50 af 0,53 nM).
Elvitegravir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.1 to 1.3 nM) and activity against HIV-2 (EC50 of 0.53 nM).
elvitegravir, et antiretroviralt lægemiddel, der kaldes en integrasehæmmer
elvitegravir, an antiretroviral medicine known as an integrase inhibitor
elvitegravir, et antiretroviralt lægemiddel, der kaldes en integrasehæmmer cobicistat, en booster (farmakokinetisk forstærkende stof) af elvitegravirs virkning
elvitegravir, an antiretroviral medicine known as an integrase inhibitor cobicistat, a booster (pharmacokinetic enhancer) of the effects of elvitegravir
Elvitegravir-eksponering i plasma er non-linær og mindre end dosisproportionel, sandsynligvis pga. opløselighedsbegrænset absorption.
Elvitegravir plasma exposures are non-linear and less than dose-proportional, likely due to solubility- limited absorption.
Elvitegravir/ cobicistat
Elvitegravir/
Elvitegravir/cobicistat (150 mg/150 mg én gang daglig)
Elvitegravir/Cobicistat (150 mg/150 mg once daily)
elvitegravir/cobicistat er ikke blevet
elvitegravir/cobicistat have not been
Elvitegravir/cobicistat/emtricitabin/tenofoviralafenamid
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Elvitegravir/cobicistat/emtricitabin/tenofovirdisoproxil
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
Elvitegravir/cobicistat/emtricitabin/tenofovirdisoproxilfumarat (fastdosiskombination)
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (fixed-dose combination)
Elvitegravir:
elvitegravir with oral
elvitegravirdosis være 150 mg en
dose of elvitegravir should be
elvitegravirdosis være 150 mg en
dose of elvitegravir should be 150 mg once daily.
elvitegravirdosis være 150 mg en gang om dagen.
150 mg once daily.
Elvitegravirresistente vira viste forskellige grader af krydsresistens over for integrase strand transfer- hæmmeren raltegravir, afhængigt af substitutionernes type og antal.
Elvitegravir-resistant viruses show varying degrees of cross-resistance to the integrase strand transfer inhibitor raltegravir depending on the type and number of substitutions.
Elvitegravirs antivirale aktivitet in vitro i kombination med antiretrovirale lægemidler fra den nukleos(t)ide reverse transkriptasehæmmer (NRTI), non-nukleoside reverse transkriptasehæmmer (NNRTI), proteasehæmmer (PI), integrase strand transfer-hæmmer, fusionshæmmer eller CCR5 co-receptor antagonistklasser udviste ingen antagonisme.
The in vitro antiviral activity of elvitegravir when combined with antiretroviral drugs from the nucleos(t)ide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), integrase strand transfer inhibitor, fusion inhibitor, or CCR5 co-receptor antagonist classes showed no antagonism.
Elvitegravirs eller cobicistats farmakokinetik hos pædiatriske personer er ikke helt klarlagt.
The pharmacokinetics of elvitegravir or cobicistat in paediatric subjects have not been fully established.
elvmord slagtilfælde (cerebrovaskulær hændelse).
uicide, stroke (cerebrovascular events).
elvmord, personlighedsforstyrrelser (adfærdsproblemer), unormal tankegang (langsom tankegang, koncentrationsbesvær)
uicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
elvmord, personlighedsforstyrrelser (adfærdsproblemer), unormal tankevirksomhed (langsom tankegang, koncentrationsbesvær);
uicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate)
elvmord, personlighedsforstyrrelser (adfærdsproblemer), unormal tankevirksomhed (langsom tankegang, koncentrationsbesvær);
uicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
elvmord, personlighedsforstyrrelser (adfærdsproblemer), unormal tankevirksomhed (langsom tankegang, koncentrationsbesvær);
uicide, personality disorders (behavioural problems),thinking abnormal (slow thinking, unable to concentrate);
elvmord, selvmordsforsøg, tanker om at skade sig selv, panikanfald, vrangforestillinger, hallucinationer,
uicide, attempted suicide, thoughts about threatening the life of yourself, panic attack, delusions, hallucination,
elvmord. slagtilfælde (cerebrovaskulær hændelse).
uicide, stroke (cerebrovascular events).
elvmordsforsøg
uicide attempts,
elvmordsforsøg og selvmordstanker, mental ubalance, abnorm adfærd, hallucinationer, vrede, forvirring, panikanfald, følelsesmæssig ustabilitet/humørsvingninger, uro
uicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;
elvmordsforsøg og selvmordstanker, mental ubalance, unormal adfærd, hallucinationer, vrede, forvirring, panikanfald, følelsesmæssig ustabilitet/humørsvingninger, rastløs uro;
uicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation
elvmordsforsøg og selvmordstanker, mental ubalance, unormal adfærd, hallucinationer, vrede, forvirring, panikanfald, følelsesmæssig ustabilitet/humørsvingninger, rastløs uro;
uicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;
elvmordsforsøg og selvmordstanker, mental ubalance, unormal adfærd, hallucinationer, vrede, forvirring, panikanfald, følelsesmæssig ustabilitet/humørsvingninger, rastløs uro;
uicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack,emotional instability/mood swings, agitation;
elvmordsforsøg, mental svækkelse, delirium
uicide attempt, mental impairment, delirium
elvmordstanker og selvmordsforsøg (hos patienter med tidligere depression eller psykiske problemer)
uicidal thoughts and suicide attempts (in patients who have had depression or mental health problems before)
elvmordstanker og selvmordsforsøg (hos patienter med tidligere depression eller psykiske problemer), depression rygsmerter på grund af nyreproblemer, inklusive nyresvigt.
uicidal ideation and suicide attempt (in patients who have had depression or mental health problems before), depression back pain caused by kidney problems, including kidney failure.
elvmordstanker, selvmordsforsøg og selvmord,
thoughts of suicide, suicide attempt and suicide,
elvmordstanker, søvnbesvær, tænderskæren eller sammenbidte tænder, desorientering, manglende motivation
uicidal thoughts, difficulty sleeping, grinding or clenching the teeth, feeling disorientated, lack of motivation
elvom du tager Baraclude, kan du stadig smitte andre med hepatitis-B virus (HBV) gennem seksuel kontakt eller kropsvæsker (fx blod).
taking Baraclude will not stop you from infecting other people with hepatitis B virus (HBV) through sexual contact or body fluids (including blood contamination).
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse.
Reproduction is authorised provided the source is acknowledged.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. behandling.
Reproduction is authorised provided the source is acknowledged. treatment.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. desuden efterfølgende kontrolleres en gang om ugen i en måned.
Reproduction is authorised provided the source is acknowledged. month when the dose is increased.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. dimethylfumarat, menes at virke ved at aktivere proteinet “Nrf2”, der regulerer visse “antioxidant”- gener, som er med til at beskytte cellerne mod beskadigelse.
Reproduction is authorised provided the source is acknowledged. certain ‘antioxidant’ genes involved in protecting cells from damage.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. fortsætte, så længe det er til fordel for patienten.
Treatment should be continued for as long as the patient benefits from it.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. immunsystemets aktivitet.
Reproduction is authorised provided the source is acknowledged. system.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. indtil den mest effektive dosis er nået.
Doses can be increased up to twice more until the most effective dose is reached.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. konstateret tarmrundorm.
Reproduction is authorised provided the source is acknowledged. diagnosed.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. nedsat nyrefunktion.
Reproduction is authorised provided the source is acknowledged.
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. overfører signaler mellem nerverne (en neurotransmitter).
Reproduction is authorised provided the source is acknowledged. those associated with gamma-aminobutyric acid (GABA), a substance which conveys messages between nerves (neurotransmitter).
EMA Gengivelse af indholdet heri er tilladt med kildeangivelse. referencelægemidlet indeholder samme aktive stof.
Reproduction is authorised provided the source is acknowledged.
EMA/11554/2011 Side 2/2
EMA/718156/2011 Page 2/2
EMA/140299/2015 Side 2/2
EMA/140299/2015 Page 2/2
EMA/14880/2015 Side 2/2
EMA/511707/2015 Page 2/2
EMA/149286/2011 Side 2/2
EMA/CHMP/149365/2011 Page 2/2
EMA/149336/2011 Side 2/2
EMA/149379/2011 Page 2/2
EMA/159853/2016 Side 2/2
EMA/159853/2016 Page 2/2
EMA/173510/2016 Side 2/2
EMA/173510/2016 Page 2/2
EMA/204489/2010 Side 2/2
EMA/218705/2010 Page 2/2
EMA/216428/2012 Side 2/2
EMA/216428/2012 Page 2/2
EMA/230894/2013 Side 2/2
EMA/230892/2013 Page 2/2
EMA/234576/2016 Side 2/2
EMA/234576/2016 Page 2/2
EMA/237070/2011 Side 2/2
EMA/925383/2011 Page 2/2
EMA/242254/2013 EMEA/H/C/001099
EMA/229550/2013 EMEA/H/C/001099
EMA/243539/2016 Side 2/2
EMA/243539/2016 Page 2/2
EMA/265372/2014 Side 2/2
EMA/CHMP/328573/2014 Page 2/2
EMA/279503/2015 Side 2/2
EMA/438073/2015 Page 2/2
EMA/284074/2016 Side 2/2
EMA/284074/2016 Page 2/2
EMA/295851/2014 Side 2/2
EMA/295851/2014 Page 2/2
EMA/300817/2013 Side 2/2
EMA/300817/2013 Page 2/2
EMA/321870/2012 Side 2/2
EMA/321870/2012 Page 2/2
EMA/335824/2014 Side 2/2
EMA/335824/2014 Page 2/2
EMA/357446/2015 Side 2/2
EMA/357446/2015 Page 2/2
EMA/383424/2015 Side 2/2
EMA/463551/2015 Page 2/2
EMA/403892/2016 Side 2/2
EMA/403892/2016 Page 2/2
EMA/404586/2013 Side 2/2
EMA/404586/2013 Page 2/2
EMA/416455/2016 Side 2/2
EMA/313571/2016 Page 2/2
EMA/422021/2014 Side 2/2
EMA/422021/2014 Page 2/2
EMA/427218/2014 Side 2/2
EMA/524629/2014 Page 2/2
EMA/429103/2013 Side 2/2
EMA/429103/2013 Page 2/2
EMA/432237/2013 Side 2/2
EMA/432244/2013 Page 2/2
EMA/439020/2015 Side 2/2
EMA/439020/2015 Page 2/2
EMA/449278/2009 Side 2/2
EMA/388793/2009 Page 2/2
EMA/450050/2016x Side 2/2
EMA/450050/2016 Page 2/2
EMA/458697/2016 Side 2/2
EMA/458697/2016 Page 2/2
EMA/464656/2009 Side 2/2
EMA/464656/2009 Page 2/2
EMA/470497/2014 Page 2/2
EMA/470505/2014 Page 2/2
EMA/478226/2016 Side 2/2
EMA/312727/2016 Page 2/2
EMA/482355/2014 Side 2/2
EMA/482355/2014 Page 2/2
EMA/499888/2010 Side 2/2
EMA/499888/2010 Page 2/2
EMA/515395/2015 Side 2/2
EMA/312188/2015 Page 2/2
EMA/516506/2015 Side 2/2
EMA/374036/2015 Page 2/2
EMA/519600/2014 Side 2/2
EMA/403410/2014 Page 2/2
EMA/552034/2007 Page 2/2
EMA/441904/2007 Page 2/2
EMA/632740/2011 Side 2/2
EMA/632740/2011 Page 2/2
EMA/634867/2015 Side 2/2
EMA/776490/2015 Page 2/2
EMA/636710/2008 EMEA/V/C/000031
EMA/573644/2008 EMEA/V/C/000031
EMA/658100/2014 Side 2/2
EMA/658100/2014 Page 2/2
EMA/65953/2015 Side 2/2
EMA/65956/2015 Page 2/2
EMA/670858/2012 Side 2/2
EMA/785026/2012 Page 2/2
EMA/685375/2012 Side 2/2
EMA/685375/2012 Page 2/2
EMA/698698/2013 Side 2/2
EMA/698698/2013 Page 2/2
EMA/712450/2015 Side 2/2
EMA/712450/2015 Page 2/2
EMA/727056/2013 Side 2/2
EMA/727056/2013 Page 2/2
EMA/743566/2013 Side 2/2
EMA/590871/2015 Page 2/2
EMA/74628/2012 EMEA/V/C/002379
EMA/97410/2011 EMEA/V/C/002379
EMA/746683/2014 Side 2/2
EMA/729961/2014 Page 2/2
EMA/75811/2016 Side 2/2
EMA/281859/2016 Page 2/2
EMA/783550/2013 Side 2/2
EMA/783550/2013 Page 2/2
EMA/805509/2014 Side 2/2
EMA/805509/2014 Page 2/2
EMA/807134/2013 Side 2/2
EMA/807134/2013 Page 2/2
EMA/807628/2012 Side 2/2
EMA/807628/2012 Page 2/2
EMA/819911/2011 Side 2/2
EMA/481432/2010 Page 2/2
EMA/CHMP/371426/2015 Side 2/2
EMA/CHMP/371429/2015 Page 2/2
EMA/CVMP/064/97 Side 2/2
EMA/CVMP/064/97 Page 2/2
EMA/CVMP/13147/2007 EMEA/V/C/000108
EMA/CVMP/431321/2006 EMEA/V/C/000108
EMA/CVMP/13169/2007 EMEA/V/C/000107
EMA/CVMP/431317/2006 EMEA/V/C/000107
EMA/CVMP/140315/2006 EMEA/V/C/000057
EMA/CVMP/221/01 EMEA/V/C/000057
EMA/CVMP/214641/2008 Side 2/2
EMA/CVMP/214641/2008 Page 2/2
EMA/CVMP/510011/2010 Side 2/2
EMA/CVMP/510011/2010 Page 2/2
EMA/CVMP/513682/2010 Side 2/2
EMA/CVMP/513682/2010 Page 2/2
EMA/CVMP/56883/2013 Side 2/2
EMA/CVMP/56883/2013 Page 2/2
Emaballage
Packaging
Emadastin difumarat er ikke fundet carcinogen i studier med mus og rotter.
Emedastine difumarate was not found to be carcinogenic in studies in mice and rats.
EMADINE 0,5 mg/ml øjendråber, opløsning i enkeltdosisbeholder.
EMADINE 0.5 mg/ml Eye Drops, solution, single-dose container.
EMADINE 0,5 mg/ml øjendråber, opløsning.
EMADINE 0.5 mg/ml Eye Drops, solution
Emadine 0,5 mg/ml øjendråber, opløsning.
EMADINE 0.5 mg/ml Eye Drops, solution.
EMADINE 0,5 mg/ml øjendråber, opløsning.
EMADINE 0.5 mg/ml Eye Drops.
EMADINE 0,5 mg/ml, Øjendråber, opløsning, enkeltdosisbeholdere.
EMADINE 0.5 mg/ml Eye Drops, solution, single-dose container.
EMADINE 0,5 mg/ml, Øjendråber, opløsning.
EMADINE 0.5 mg/ml, Eye Drops, solution
EMADINE 0,5 mg/ml, øjendråber, opløsning, enkeltdosisbeholdere.
EMADINE 0.5 mg/ml Eye Drops, solution, single-dose container.
Emadine anbefales ikke til patienter med nyre- eller leverproblemer.
EMADINE is not recommended for use in patients with kidney or liver problems.
Emadine anbefales ikke til patienter over 65 år, da der ikke er udført kliniske studier på denne aldersgruppe.
EMADINE is not recommended for use in patients over 65 years of age, as it has not been studied in clinical trials in this age group.
EMADINE bør ikke anvendes længere end 4 uger efter første åbning af flasken..
EMADINE should not be used for longer than 4 weeks after first opening.
Emadine er en væske (en opløsning), der fås i 5 ml eller 10 ml plastikflasker (DROP-TAINER) med skruelåg.
EMADINE is a liquid (a solution) supplied in a pack containing a 5 ml or 10 ml plastic (DROP-TAINER) bottle with a screw cap.
Emadine er en væske (opløsning), der fås i enkeltdosisbeholdere af plastik indeholdende 0,35 ml.
EMADINE is a liquid (a solution) supplied in single-dose plastic containers which contain 0.35 ml.
EMADINE er ikke undersøgt i studier af mere end seks ugers varighed.
EMADINE has not been studied in clinical trials beyond six weeks.
EMADINE har ikke været undersøgt hos patienter over 65 år og kan derfor ikke anbefales til denne patientgruppe.
EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population.
Emadine indeholder et konserveringsmiddel (benzalkoniumchlorid), som kan give irritation af øjnene og misfarve bløde kontaktlinser.
A preservative in EMADINE (benzalkonium chloride) may cause eye irritation and is known to discolour soft contact lenses.
EMADINE kan anvendes til børn (fra 3 år og opefter) med samme dosering som til voksne.
EMADINE may be used in paediatric patients (3 years of age and older) at the same posology as in adults.
EMADINE kan anvendes til børn fra (3 år og opefter) med samme dosering som til voksne.
EMADINE may be used in paediatric patients (3 years of age and older) at the same posology as in adults.
Emadine kan ikke anbefales til patienter med nyre- eller leverproblemer.
EMADINE is not recommended for use in patients with kidney or liver problems.